The Current and Evolving Role of Translational Research ("Where We Are") {#s1}
========================================================================

The Current Landscape {#s1-1}
---------------------

Translational research is challenged to speed the advancement of innovations likely to improve clinical and population health. Within this enterprise, dissemination and implementation (D&I) research is well positioned to optimize the adoption and implementation of emerging evidence within practice settings. However, D&I research has often attended only to the implementation of long-standing, well-established practices and programs. This has situated D&I research as the final step within a linear sequence of phased trials (i.e., discovery, efficacy, effectiveness, and implementation) and translational science paradigm (i.e., T0→T4 research) -- a constrained role creating unnecessary lags in translation.

To advance a more robust and expediting role for D&I research, we acknowledge two well-documented foundations (*premises*) in the translation of evidence to practice followed by a select set of more provocative viewpoints (*hot-takes*; See Table [1](#tbl1){ref-type="table"}).

Table 1.Premises and hot-takes in translating evidence to practice**Key Premise \#1**Translation of evidence to practice is unnecessarily slow.*Hot-Take \#1*Dissemination and implementation research should not be viewed merely as a final step in the translational process.*Hot-Take \#2*Without radically different approaches to accelerating translation, implementation of evidence to practice will remain slow.**Key Premise \#2**Translation of evidence to practice is a dynamic process.*Hot-Take \#3*Researchers are responsible for considering implementation needs "early and often" for accelerated and dynamic translation.*Hot-Take \#4*All health research should aim to address an actual problem or need, with an expectation of ongoing iterative improvements.*Hot-Take \#5*Much evidence can be acted upon even when uncertainty is moderately high, recognizing that this evidence is evolving and subject to frequent reevaluation.

An established goal of D&I research is to ensure more timely translation of evidence to practice, largely in response to the documented 17-year translational gap \[[@ref1]\]. Despite working toward this end for more than a decade, evidence of clear progress is scant. The gap continues to widen when implementation is merely "left as a posthoc procedure" \[[@ref2]\]. The translational science community must also reconcile the need for scientific rigor with the recognition that evidence is always evolving and imperfect. Via paradigms such as the "lean startup" concept \[[@ref3]\], entrepreneurship may provide guidance on balancing this tension between rigor and a learning mindset.

Furthermore, D&I research is generally reactive, with an eye toward identifying barriers to then address. However, reactivity creates an inherent lag. More efficient approaches are anticipatory, designing strategies to fit the context in which the innovation will be implemented \[[@ref4]\]. Making these anticipatory strategies more adaptive, robust, and sustainable in complex healthcare systems can maximize the clinical and population health benefit of promising innovations.

Designing for Accelerated Translation (DART) of Emerging Innovations ("Where We Want to Be") {#s2}
============================================================================================

Demand, Risk, Cost, and the Pace of Translation {#s2-1}
-----------------------------------------------

A perennial question among the translational science community is "When can we begin acting on the evidence we have?" For D&I research, this is often interpreted as "What is the minimum level of evidence needed for implementation?" This question reflects an assumption that a minimum threshold of evidence is the primary impetus of translation. We assert that additional factors -- *demand*, *risk*, and *cost*, in addition to the *evolving evidence* base -- should influence the pace of translation over time. Attention to these underemphasized factors leads to more dynamic decision-making about whether or not to adopt an emerging innovation or de-implement a suboptimal intervention.

Given complexities in decision-making based on the risk--benefit ratio for promising innovations, it is useful to generate testable hypotheses about circumstances that drive use of evidence to inform next steps prior to large-scale implementation. We suggest that the *pace* of translation (*P*) is a function of the strength of evidence supporting the *effectiveness* (*E*) of the innovation, multiplied by the sum of stakeholder estimates of the *demand* (*D*, factoring in urgency, existing alternatives, and stakeholder pull), divided by the sum of *risks* (*R*, viewed here as a ratio of risk of potential clinical harms of the innovation (*R* ~*Innovation*~) balanced by risks associated with not acting on the available evidence or with maintaining the status quo (*R* ~*Status\ quo*~); for instance, *R* = *R*~*Innovation*~/*R* ~*Status\ quo*~), and *costs* (*C*, factoring in financial expense, resource intensiveness, and disruptive effects) of the innovation:

The equation may serve as a heuristic, indicating that if either the evidence of effectiveness is very weak or if demand for the innovation is very low, then movement toward implementation should come to a halt. The influence of these factors is moderated by a denominator that includes risk and cost, such that the pace of translation is relatively unaffected when the risks and costs of implementation are low yet the pace of translation is substantially reduced when risks and costs are high. One might hypothesize that an innovation with limited existing evidence of effectiveness yet high demand and low risk and cost may be a better candidate for accelerated translation than one with strong evidence yet low demand and high risk and cost. We encourage investigators to test this type of hypothesis through observation of naturally occurring implementation efforts involving innovations with different profiles of effectiveness evidence, demand, risk, and cost. These factors could also be varied prospectively to test the effects on the pace of implementation. Finally, we expect that other factors could and should be added to the proposed equation as hypothesized drivers of implementation.

A Paradigm Shift {#s2-2}
----------------

Rapid advancements in technology and precision medicine (e.g., genomics) indicate the need for a faster pace of translational research \[[@ref5]--[@ref7]\]. Still, few heuristics exist to guide scientific approaches to accelerating research to practice. We present a conceptual architecture for speeding the translation potential for emerging innovations that demonstrate promising utility. Our framework to ***D***esign for ***A***ccele***r***ated ***T***ranslation (DART) is the product of synthesizing related yet inadequately linked areas of science into a cohesive three-pronged agenda focused on meaningful stakeholder partnership, designing innovations for D&I, and a learning health system (see Fig. [1](#f1){ref-type="fig"} and Table [2](#tbl2){ref-type="table"}):*Forming meaningful stakeholder partnerships*, including participation in team science, citizen science, and public--private partnerships.*Designing innovations for D&I*, including eliciting demand, incorporating user-centered design, and prioritizing adoption potential.*Engaging in a learning health system*, including fostering an agile workforce, monitoring the effect of a new innovation and providing iterative feedback, and performing ongoing evidence review.

Fig. 1.Design for Accelerated Translation (DART) framework. Forming meaningful stakeholder partnerships, designing innovations for dissemination and implementation (D&I), and engaging in a learning health system as a three-pronged approach to accelerate translation of emerging innovations in practice.

Table 2.Design for Accelerated Translation (DART) strategies to optimize the implementation of emerging health innovationsCurrent State:\
"Where We Are"Optimal State:\
"Where We Want to Be"Improvement Strategies:\
"What It Will Take"**Meaningful Stakeholder Partnership**Disconnected from customers; Lab silosUtilizing team scienceDevelop partnerships between investigators across the translational spectrum early in design/developmentSmall/restrictive samplesLeveraging citizen scienceHarness power of public for scientific activitiesDisconnected from industryPartnering with private industryPartner with those primed to bring innovations to market**Design Innovations for D&I**Pushing out innovationsEliciting demand and performance needs from usersUnderstand user motives and context; demonstrate value added and simplicityResearcher-driven developmentEngaging in human/user-centered designInvolve diverse group of end-users as partners throughout design/developmentEfficacy over effectivenessImplementing robust, context-sensitive innovationsBetter packaging of research evidence for translation to practice and policy; focus on pragmatic and adaptive trials to optimize adoption potential**Learning Health System**Rigid/narrow use of evidenceOngoing and efficient review of evidenceUse existing data to add to evidence on intervention impact; conduct rapid reviews; use create--trial--sustain approaches to guide ongoing adaptationStatic delivery systemsSupporting the use of iterative feedbackGive real-time feedback on key outcomes to providersResistant to changePromoting an agile workforce with change-oriented mindsetTrain workforce in core concepts that apply across technologiesD&I, Dissemination and Implementation.

The DART framework aims to clarify whether, when, and how to act on evolving evidence to address identified needs in healthcare. We challenge the field to embrace a new way of approaching D&I research that prioritizes acceleration for innovations that can provide immediate clinical benefit and be improved over time. To achieve the goals envisioned by the DART framework, the D&I and translational science communities will need to engage in a set of improvement strategies to move from a system characterized as siloed, slow, and static toward an optimized system featuring powerful stakeholder engagement, innovations designed for D&I, and learning health system principles.

Strategies to Achieve DART ("What It Will Take") {#s3}
================================================

Meaningful Stakeholder Partnership {#s3-1}
----------------------------------

The scientific enterprise is criticized for being overly homogenous in collaboration, disconnected from consumers (e.g., patients, caregivers, providers, manufacturers), and slow to translate evidence to practice. To dismantle these perceptions, team science should be stretched to the fullest extent, fostering teamwork between D&I scientists and discovery scientists engaged in research pertinent to elucidation of disease processes which might lead to novel approaches to prevention, diagnosis, or treatment of disease. Bench scientists might consider the direction and translation potential of their discoveries, in partnership with both translational researchers and customers. Intervention developers might prioritize identifying an important problem to address with an appropriate solution rather than pushing their developed tool toward the next possible target. Effectiveness researchers might address D&I research questions (e.g., what disruption is caused). Finally, D&I scientists might feed insights back to bench scientists and community partners to inform future directions of early-stage translational science. At the point of bringing discovery science into clinical investigation, a team approach spanning the translational science spectrum could accelerate overall success.

Citizen science, or collaboration between members of the public and professional scientists to collect and process large quantities of data, offers distinct opportunities to harness the power, bandwidth, and unique insights of the public for scientific activities \[[@ref8]\]. Wearable technologies (e.g., activity trackers) and direct-to-consumer genetic testing (e.g., 23andMe) are now ubiquitous and poised to integrate with routine clinical care. In addition, families are leveraging social media to study rare diseases \[[@ref9]\]. Community-driven research approaches prioritize focus in areas of true need and in partnership with stakeholders well positioned to apply context-appropriate solutions. Finally, private industry is primed to bring innovations to market, and entrepreneurs and technology development firms can help researchers rapidly move tested products into the hands of consumers.

Designing Innovations for D&I {#s3-2}
-----------------------------

Knowing the problem and context for implementation, including stakeholder needs, motives, and preferences, is a critical precondition to effectively designing solutions primed for D&I \[[@ref10]\]. Potential users will only "pull" for emerging innovations demonstrated to be more effective or easier to use than alternatives. Innovators must also address financial issues of cost for consumers and reimbursement options for providers (e.g., pay for performance, prospective payment systems). Innovation design should prioritize meeting identified user needs, using iterative feedback to optimize design \[[@ref11]\]. However, diverse groups of potential end-users and ancillary stakeholders should be engaged throughout the process, not simply in refinement or optimization stages. In general, innovation translation is enhanced by executing user-driven priorities, not researcher-driven assumptions. Researchers should be trained to package evidence in ways that meet practitioner and policymaker needs. Concerted efforts to improve packaging of evidence for translation will make this information more actionable to those driving real-world change \[[@ref12]--[@ref14]\].

Learning Health System {#s3-3}
----------------------

Shaping a dynamic, agile, and efficient healthcare system requires researchers, providers, patients, and administrators to think differently about how they plan, collect, and respond to data. This transformation encourages replacing lengthy and tightly controlled trials with opportunities for timely learning, and a willingness to act on equivocal evidence recognizing that evidence best evolves through testing in externally valid contexts. With continuous learning as a priority, ongoing review of an ever-evolving evidence base is essential. When higher-burden systematic reviews are considered infeasible, organizational leaders may opt for rapid reviews to inform decision-making, focusing on real-world data from highly pragmatic comparative effectiveness research. Providers should also have access to personalized, near real-time performance data relative to benchmarks to inform, reinforce, and motivate optimal service delivery \[[@ref15]\]. Create--trial--sustain approaches prioritize first solving a tangible problem with an unrefined innovation in a limited context \[[@ref16]\]; this ensures feasibility and potential for scale-up and sustainability prior to investing resources in further development, testing, and optimization. Lastly, healthcare systems that expect support and reward responsiveness to new evidence help to foster a more agile, change-oriented workforce adaptable to frequent shifts in technology. An agile healthcare workforce can accelerate the impact of emerging innovations by anticipating and planning for the future, rather than current, healthcare system.

Contextual Domains of Activity {#s3-4}
------------------------------

To effectively execute the above three-pronged approach, each DART component -- meaningful stakeholder partnership, innovations designed for D&I, and a learning health system -- is greatly influenced by the context for implementation, or the constellation of interacting factors and circumstances that surround a particular implementation effort \[[@ref17]\]. Frameworks to understand implementation context abound and most include the organizational setting (e.g., clinic, community), individuals involved (e.g., healthcare providers, end-users), and characteristics of the innovation itself (e.g., design quality and packaging, adaptability) among the important contextual domains \[[@ref17]--[@ref19]\]. As illustrated in Fig. [1](#f1){ref-type="fig"}, one or more of these contextual domains reside at the nexus between each DART component. For instance, efforts to conduct meaningful stakeholder partnership and/or design innovations for D&I rely on a robust understanding of both the potential end-users of the innovation and the broader communities involved in the implementation effort. Designing innovations for D&I and/or employing a learning health system requires extensive focus on the characteristics of the innovation and necessary adaptations to enhance fit with the local context. Finally, engaging in successful learning health system and meaningful stakeholder partnership activities depends upon being sensitive and responsive to the needs of the clinical or other organizational setting and the teams of individuals (e.g., decision-makers, care teams, patients) actively involved in the implementation process. Active consideration of each of these contextual domains is likely to help synergize the joint efforts of each DART component. As such, context can be viewed as the "glue" that binds the other elements of the DART framework.

Potential Approaches to DART {#s3-5}
----------------------------

How can researchers and consumers accelerate the evidence translation? We offer three potential approaches: *anticipatory*, *simultaneous*, and *hybrid*.

Anticipatory approaches focus on taking steps to prevent implementation barriers before they arise. Key stakeholders, champions, and change agents are engaged early and throughout the process. Intervention designers learn the local practice context while end-users inform design and testing; together they align the intervention with local and national priorities, including those pertaining to policy and payment. Stakeholders may also leverage networks and social media to build urgency and demand.

Simultaneous approaches use rapid-cycle and iterative design to accelerate and optimize an innovation. Intervention researchers can employ user/human-centered design principles to shape minimally viable products, continuously refined through stakeholder feedback. Simultaneous work on design and translation may function best in learning health systems marked by frequent efforts to align innovations and settings.

Finally, hybrid approaches combine anticipatory and simultaneous principles, often involving early-stage trialing at local or system levels. These approaches afford intervention developers the opportunity to fail "safely," identify contextual fault lines, and continually refine processes for larger-scale implementation.

Areas Primed for DART Approaches {#s4}
================================

DART approaches are widely applicable to the majority of research domains. While it is "never too soon" to think about accelerating translation, it is also "never too late" to make translation more dynamic through ongoing evaluation and improvements for a broad range of innovations. We highlight certain areas -- including *genomic medicine* and *mHealth* -- that are particularly ripe for utilizing DART approaches. Such examples are both *emergent* and *evolving* in nature, as vast advancements have recently been made and are likely to continue fluctuating.

Emergent Considerations {#s4-1}
-----------------------

Genomic medicine and mHealth tools afford unique opportunities to design for D&I at the outset, drive learning health system efforts with new windfalls of data, and engage transdisciplinary groups of stakeholders in novel ways. Rapid-cycle and iterative design with innovation developers and users is most naturally conducted with newer innovations that have not yet established stable patterns of use. Even when the rate of implementation must be moderated by forthcoming effectiveness data, innovation teams can maintain the pace of translation by utilizing anticipatory DART approaches.

For instance, many promising genomic innovations have demonstrated solid analytic and clinical validity with uncertain clinical utility. Researchers can accelerate translation here through anticipatory approaches, collecting pre-implementation data on local context and end-users alongside clinical effectiveness and utility data. Relatedly, although evidence clearly supports genetic testing for high risk of colon cancer, this innovation cannot have any major public health impact in the absence of a system that delivers colon cancer screening and subsequent therapy in a reliable and efficient manner, ideally also addressing equity. Therefore, joint consideration of implementation and health system approaches while developing the test would accelerate adoption. Thinking ahead about the full continuum of care involved with genomic innovations may also speed translation. Instead of focusing narrowly on genetic testing, researchers can impact the broader cascade of care, including interpretation, follow-up, preventative care, and treatment informed by genomic information. Ultimately, a comprehensive understanding of this full continuum is needed to enable implementation, and holistic approaches will likely advance translation more quickly than piecemeal ones.

Evolutionary Considerations {#s4-2}
---------------------------

As genomics and mHealth innovations are in flux, we must manage the uncertainty of forthcoming evidence and ongoing iterative refinement. In tandem with the emphasis on rapid acceleration, there is an important opportunity to focus on evolution in these areas over time, rather than the traditional view of an intervention that moves unidirectionally from bench to bedside.

Technology can be a key component of treatment support for many people. However, consumer interaction with mHealth interventions varies and may wane quickly upon experiencing diminished returns. However, given vast learning capacities of GPS functionality, smartphone engagement patterns, ecological momentary assessment and intervention, mHealth tools can respond to evolving user needs and preferences and guide ongoing treatment adaptation to provide the right type of support at the right time and place.

Conclusion {#s5}
==========

The DART framework offers a contrast to the traditional linear view of the translational pathway, recognizing that in the dynamic, rapidly evolving healthcare ecosystem, we can no longer wait for the slow, steady progress from intervention development, through testing, and ultimately into real-world implementation. Instead, we must look across the translational spectrum for ways to refine and redefine each step along the path.

We propose DART as a framework that applies across multiple domains of healthcare and health (clinical, community/public health), with specific use for areas of biomedical research in which rapid progress is expected (e.g., genomic medicine, mHealth). It has, at its core, four key objectives that reshape our view of the translational pathway:Better linkages between research teams (team science) and between researchers and those who can drive, steer, and land one's innovation (industry, community, citizen science).Improved design of innovations for optimal use/actionability (design for D&I).Simultaneous learning about adapting interventions in response to evolving evidence (learning health system).Consideration of demand, risk (including risk of not implementing), and cost of the innovation to optimize the rate of implementation.

While we recognize the need for more work to operationalize the framework, we expect that the field can already contribute by chronicling specific biomedical innovation examples in which iterative testing and implementation has sped the translational cycle. We look forward to ongoing dialog about how key stakeholders in translational science can better support these principles in the context of their research programs. In collaboration, we can greatly improve the ongoing innovation, analysis, and improvement of our health and healthcare systems.
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